Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma

Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiao Chen, Dongdong Wang, Guangfei Wang, Yidie Huang, Xin Yu, Jinmiao Lu, Xiaowen Zhai, Hong Xu, Zhiping Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	optimization initial dose regimen sirolimus pediatric lymphangioma Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c13e6d3278264d2a93c807a78e5b9a71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c13e6d3278264d2a93c807a78e5b9a71
record_format	dspace
spelling	oai:doaj.org-article:c13e6d3278264d2a93c807a78e5b9a712021-11-08T08:09:53ZOptimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma1663-981210.3389/fphar.2021.668952https://doaj.org/article/c13e6d3278264d2a93c807a78e5b9a712021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.668952/fullhttps://doaj.org/toc/1663-9812Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future.Xiao ChenDongdong WangGuangfei WangYidie HuangXin YuJinmiao LuXiaowen ZhaiHong XuZhiping LiFrontiers Media S.A.articleoptimizationinitial dose regimensirolimuspediatriclymphangiomaTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	optimization initial dose regimen sirolimus pediatric lymphangioma Therapeutics. Pharmacology RM1-950
spellingShingle	optimization initial dose regimen sirolimus pediatric lymphangioma Therapeutics. Pharmacology RM1-950 Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
description	Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future.
format	article
author	Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li
author_facet	Xiao Chen Dongdong Wang Guangfei Wang Yidie Huang Xin Yu Jinmiao Lu Xiaowen Zhai Hong Xu Zhiping Li
author_sort	Xiao Chen
title	Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_short	Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_full	Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_fullStr	Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_full_unstemmed	Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
title_sort	optimization of initial dose regimen for sirolimus in pediatric patients with lymphangioma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c13e6d3278264d2a93c807a78e5b9a71
work_keys_str_mv	AT xiaochen optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT dongdongwang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT guangfeiwang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT yidiehuang optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT xinyu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT jinmiaolu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT xiaowenzhai optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT hongxu optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT zhipingli optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma
_version_	1718442849320566784

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma

Ejemplares similares